Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Hemay005 Formulations in Healthy Subjects
NCT06610903Phase 1Completed
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Sep 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mufemilast in psoriasis (2 arms), sponsored by Hemay Pharmaceutical Technology. Primary endpoints: Peak Plasma Concentration, Area under the plasma concentration versus time curve from time 0 to time t and 1 more. Started Sep 2024; status: completed.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06610903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610903.